Cardiovascular aspects of antipsychotics
Abstract
Purpose of review Schizophrenia is associated with increased mortality and reduced life expectancy, with cardiovascular disease being the most frequent cause of death. Antipsychotics have detrimental effects on different risk factors for cardiovascular disease. This review will focus on the relationship between antipsychotic treatment and cardiovascular disease. Recent findings The increased overall mortality and mortality from cardiovascular disease in schizophrenia are now well documented. Patients with schizophrenia are at risk of receiving less optimal treatment for cardiovascular disease. Patients with schizophrenia are at high risk of metabolic syndrome, a cluster of risk factors for cardiovascular disease. Some antipsychotics, in particular, clozapine and olanzapine, frequently cause weight gain, dyslipidemia and diabetes mellitus. Antipsychotics differ in their effects on body weight, lipids and glucose regulation. However, the long-term effects of these differences between individual antipsychotics on overall mortality and cardiovascular mortality are not well established. Summary More research is needed to better understand the relationship between schizophrenia, antipsychotic treatment and cardiovascular disease. More effective treatment strategies need to be developed to reduce the burden of cardiovascular disease in schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Raedler 2010 concluded antipsychotics increased risk of metabolic syndrome, sudden cardiac death, and myocarditis/cardiomyopathy.
“Raedler (2010) reviewed the effect of antipsychotic drugs and concluded that antipsychotics increased the risk of metabolic syndrome, sudden cardiac death, and myocarditis/cardiomyopathy.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Raedler 2010
No evidence suggested that risk varied by type of antipsychotic drugs.
“However, no evidence suggested that the risk varied by type of antipsychotic drugs.”
From Excess early mortality in schizophrenia. (2014) · cites this paper as Raedler 2010
Cites
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869 · see citing works
Twenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601 · see citing works
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433 · see citing works
Mortality and Medical Comorbidity Among Patients With Serious Mental Illness
Miller, B. J., Paschall, C. B., & Svendsen, D. P. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.10.1482 · Cited by 275 · see citing works
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223 · see citing works
Birkenaes, A. B., Opjordsmoen, S., Brunborg, C., Engh, J. A., Jonsdottir, H., Ringen, P. A., Simonsen, C., Vaskinn, A., Birkeland, K. I., Friis, S., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0614 · Cited by 185 · see citing works
Bobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181 · see citing works
Cancer mortality in patients with schizophrenia: An 11‐year prospective cohort study
Tran, E., Rouillon, F., Loze, J., Casadebaig, F., Philippe, A., Vitry, F., & Limosin, F. (2009) · Cancer · doi:10.1002/cncr.24383 · Cited by 173 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Premature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083 · see citing works
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · see citing works
Laursen, T. M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Nordentoft, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067133 · Cited by 313 · see citing works
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Leung, J. Y. T., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.003 · Cited by 163 · see citing works
- Authors
- Raedler, T. J.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Raedler, Thomas J
- ORCID
- Raedler, Thomas J
- Venue
- Current Opinion in Psychiatry
- Published
- 2010-11
- Volume
- 23
- Issue
- 6
- Pages
- 574-581
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2041975665
- Cited by
- 89
- References
- 10
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 11 · 2017: 2 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 13
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
- Keywords
- antipsychotic drugs, cardiovascular disease, schizophrenia, mortality, metabolic syndrome, clozapine, olanzapine, weight gain, dyslipidemia, diabetes mellitus, glucose regulation, cardiovascular risk factors
- MeSH terms
- Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Cardiomyopathies, Myocarditis, Risk Factors, Schizophrenia, Antipsychotic Agents, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
